Want to see TSE:EBM full AI Analyst Report?

Eastwood Bio-Medical Canada (EBM) Price & Analysis

5 Followers

EBM Stock Chart & Stats

C$0.99

C$0.01(1.02%)

At close: Jul 24 4:00 PM EDT

C$0.99

C$0.01(1.02%)

Day’s Range― - ―

52-Week RangeC$0.30 - C$1.19

Previous CloseN/A

Volume509.00

Average Volume (3M)3.49K

Market Cap

C$66.82M

Enterprise ValueC$67.41M

Total Cash (Recent Filing)C$9.04K

Total Debt (Recent Filing)C$67.98K

Price to Earnings (P/E)―

Beta-1.08

Next Earnings

Sep 24, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)>-0.01

Shares Outstanding68,885,970

10 Day Avg. Volume3,055

30 Day Avg. Volume3,488

Financial Highlights & Ratios

PEG Ratio5.35

Price to Book (P/B)-29.59

Price to Sales (P/S)61.66

P/FCF Ratio2.50K

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Revenue MomentumSustained topline growth (~+9.5% TTM) indicates rising demand and market traction for the company's offerings. Over 2–6 months this supports scaling benefits, improves leverage on fixed costs, and provides a foundation to convert higher gross margins into lasting operating improvements if cost structure is controlled.

Improving Cash GenerationThe shift to slightly positive operating and free cash flow signals improving ability to fund operations from internal sources. If sustained, this reduces reliance on external financing, enhances near-term liquidity, and supports reinvestment or debt repayment over the medium term, strengthening durability of the business.

Modest Absolute DebtRelatively low absolute debt levels limit immediate solvency pressure and reduce mandatory interest/service burdens. This provides more strategic flexibility to manage the turnaround, negotiate with creditors, or fund operations while addressing negative equity, improving survivability during restructuring or growth execution.

Bears Say

Sustained Net LossesLarge, persistent operating and net losses erode capital and curtail the company's ability to self‑finance growth or absorb shocks. Over months this limits reinvestment in distribution capabilities, weakens negotiating leverage with suppliers, and forces reliance on external capital or dilution to cover ongoing deficits.

Negative Shareholders' EquityPersistent negative shareholders' equity materially raises financial risk and constrains strategic options. It distorts leverage metrics, deters unsecured financing, increases covenant and refinancing risk, and makes the company more vulnerable to creditor action or dilution without meaningful operational improvement.

Volatile And Small Free Cash FlowVolatile and modest free cash flow undermines reliable funding for working capital and capex. Sharp swings reduce forecastability, force short-term financing dependence, and mean that even occasional positive FCF may be insufficient relative to ongoing losses, raising longer‑term sustainability concerns.

EBM FAQ

What was Eastwood Bio-Medical Canada Inc’s price range in the past 12 months?

Eastwood Bio-Medical Canada Inc lowest stock price was C$0.30 and its highest was C$1.19 in the past 12 months.

What is Eastwood Bio-Medical Canada Inc’s market cap?

Eastwood Bio-Medical Canada Inc’s market cap is C$66.82M.

When is Eastwood Bio-Medical Canada Inc’s upcoming earnings report date?

Eastwood Bio-Medical Canada Inc’s upcoming earnings report date is Sep 24, 2026 which is in 49 days.

How were Eastwood Bio-Medical Canada Inc’s earnings last quarter?

Eastwood Bio-Medical Canada Inc released its earnings results on Jun 29, 2026. The company reported -C$0.001 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.001.

Is Eastwood Bio-Medical Canada Inc overvalued?

According to Wall Street analysts Eastwood Bio-Medical Canada Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Eastwood Bio-Medical Canada Inc pay dividends?

Eastwood Bio-Medical Canada Inc does not currently pay dividends.

What is Eastwood Bio-Medical Canada Inc’s EPS estimate?

Eastwood Bio-Medical Canada Inc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Eastwood Bio-Medical Canada Inc have?

Eastwood Bio-Medical Canada Inc has 68,885,970 shares outstanding.

What happened to Eastwood Bio-Medical Canada Inc’s price movement after its last earnings report?

Eastwood Bio-Medical Canada Inc reported an EPS of -C$0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Eastwood Bio-Medical Canada Inc?

Currently, no hedge funds are holding shares in TSE:EBM

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Eastwood Bio-Medical Canada Inc

Eastwood Bio-Medical Canada Inc., established in Richmond, Canada, in 2010, is a company focused on the worldwide marketing and distribution of natural health products. Operating under the Eleotin brand, their offerings are available across Canada, the United States, and Asian regions. The firm's core mission is to deliver natural remedies for prevalent metabolic disorders, including issues with blood glucose regulation, hypertension, and obesity. Their extensive portfolio of licensed Eleotin products addresses diverse health requirements. For individuals experiencing spleen deficiency, appetite loss, or fatigue, Eleotin A 700 provides support. Eleotin AL88 serves as a laxative, while Eleotin Cal20 aids in the maintenance of healthy bones and teeth. Eleotin V3D is formulated for the development and upkeep of strong bones, teeth, and overall well-being. To support cardiovascular health, they offer Eleotin G2000. Eleotin H55 is designed to act as a sedative and alleviate tension, and Eleotin Zn330 is vital for tissue formation and metabolic processes. Furthermore, their product line includes Eleotin Bentley, which promotes balanced glucose levels, and Eleotin LBM, intended for hypertension relief.